How IDEXX Laboratories Makes Money

IDEXX operates a classic, highly profitable razor-and-blade business model centered on long-term veterinary clinic relationships. The company places in-clinic diagnostic instruments (chemistry, hematology, and urinalysis analyzers) in veterinary clinics under multi-year customer commitments (typically 6-year contracts). Once an analyzer is installed, the clinic must exclusively purchase IDEXX's proprietary, single-use test slides, reagent packs, and calibration cartridges for every diagnostic test run on a sick or wellness pet, generating recurring, high-margin consumable revenue. CAG Diagnostics Recurring Revenue (consumables, reference lab tests, and software subscriptions) accounts for over 90% of total company revenue. In veterinary software, IDEXX charges recurring monthly SaaS fees for cloud practice management platforms (ezyVet) and digital imaging storage.

IDEXX's forward growth strategy centers on three secular expansion drivers: expanding international in-clinic analyzer placements, driving veterinary practice software migration to the cloud, and commercializing novel diagnostic biomarkers. Internationally, veterinary diagnostic testing frequency per pet in Europe, Japan, and Latin America is less than half the US level; IDEXX is rapidly deploying direct sales teams across international markets to capture extensive overseas testing adoption. In software, IDEXX is migrating clinics from legacy on-premise software to cloud-native ezyVet, which automates billing and integrates diagnostic orders seamlessly. In assay innovation, IDEXX is expanding early cancer screening and feline infectious disease test panels to detect illnesses years before clinical symptoms emerge.